« Roche: Layoffs, or Rumors? |
| Nanopowders? »
August 30, 2010
Avastin For Metastatic Breast Cancer: The Whole Story
Here's an excellent roundup of the Avastin story, referenced in an earlier post here.
I have to say, I've been disappointed in some of the commentary on this issue (which that article goes into as well). Too many people have jumped right to the conclusion that yep, here's what the new health care plan is going to do to us, yank life-saving medicines out of our hands because they cost too much. Well, I think that the health care bill was a disastrous idea, myself, and at the same time I still think that Avastin doesn't deserve approval for metastatic breast cancer.
The best evidence we have is that Avastin doesn't help these patients and may well even hurt them. That would be true even if it were free. And remember, off-label use is still perfectly legal. Anyone who wishes to spend their own money on something that does not appear to work - and that Wall Street Journal editorial aside, Avastin really doesn't, here - is free to do so. Getting everyone else to pay for it is quite another thing, and you'd think that conservatives and libertarians would find that argument more appealing than they seem to.
The FDA meets to discuss this issue on September 17. I wish everyone who's gearing up to write editorials about the decision would get up to speed on the facts before then.
+ TrackBacks (0) | Category: Cancer | Drug Prices | Regulatory Affairs
POST A COMMENT
- RELATED ENTRIES
- Abandoned Pharma
- Targacept Comes Up Empty, Yet Again
- Summer Blogging
- The Antibiotic Gap: It's All of the Above
- Phenotypic Assays in Cancer Drug Discovery
- Neratinib Comes Through For Puma
- How Many Biopharma Employees Would Rather Be Working Somewhere Else?
- The Broad Gets $650 Million For Psychiatric Research